Legend Biotech director reports initial share holdings

Legend Biotech Corp director Sanders Corazon (Corsee) D. has reported her initial equity holdings in the company.

Rhea-AI Filing Summary

Legend Biotech Corp director Sanders Corazon (Corsee) D. has reported her initial equity holdings in the company. She holds 59,115 ordinary shares directly, which include 25,674 restricted share units that convert into one ordinary share each upon settlement.

She also holds a share option for 12,000 ordinary shares at an exercise price of $11.50 per share, expiring on June 5, 2030, and all of these option shares are immediately exercisable. The restricted share units vest in multiple quarterly installments beginning March 20, 2026 and June 20, 2026, subject to continued service. Each American Depositary Share represents two ordinary shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sanders Corazon (Corsee) D.

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (right to buy) — 12,000 contracts (Direct); Ordinary Shares — 59,115 shares (Direct)

Footnotes (3)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. F2. Includes 25,674 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 7,136 RSUs have settled, with the remainder vesting (i) as to 2,100 RSUs, in 3 equal quarterly installments beginning on March 20, 2026, (ii) as to 5,888 RSUs, in 7 equal quarterly installments beginning on March 20, 2026, and (iii) as to 10,550 RSUs, with 25% of the shares vesting on June 20, 2026 with the remainder vesting 7 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
3. F3. All of the shares subject to the option are immediately exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity stake does Sanders Corazon D. report in Legend Biotech (LEGN)?

Sanders Corazon (Corsee) D. reports direct ownership of 59,115 Legend Biotech ordinary shares. This total includes 25,674 restricted share units that can settle into ordinary shares, giving a clear picture of her initial equity position as a director in the company.

What stock options does Sanders Corazon D. hold in Legend Biotech (LEGN)?

She holds a share option covering 12,000 Legend Biotech ordinary shares at an exercise price of $11.50. The option is immediately exercisable and expires on June 5, 2030, providing long-dated potential ownership if exercised during the option term.

How do Sanders Corazon D.’s RSUs in Legend Biotech (LEGN) vest?

She holds 25,674 restricted share units that vest in staged quarterly installments beginning March 20, 2026 and June 20, 2026. A portion has already settled, and remaining tranches depend on her continued service with Legend Biotech on each vesting date.

How are Legend Biotech (LEGN) ordinary shares represented by ADSs for this director?

Legend Biotech’s ordinary shares may be represented by American Depositary Shares, with each ADS corresponding to two ordinary shares. This means the director’s reported ordinary share and option positions can also be viewed in ADS terms using that stated two-to-one ratio.

Does this Legend Biotech (LEGN) Form 3 show any recent insider buying or selling?

No specific buy or sell transactions are shown; the Form 3 reports existing holdings. It lists the director’s ordinary shares, restricted share units, and options, establishing her initial ownership and equity-based compensation position rather than disclosing new trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 06:51 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sanders Corazon (Corsee) D.

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	59,115(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(3)	06/05/2030	Ordinary Shares	12,000	$11.5	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Includes 25,674 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 7,136 RSUs have settled, with the remainder vesting (i) as to 2,100 RSUs, in 3 equal quarterly installments beginning on March 20, 2026, (ii) as to 5,888 RSUs, in 7 equal quarterly installments beginning on March 20, 2026, and (iii) as to 10,550 RSUs, with 25% of the shares vesting on June 20, 2026 with the remainder vesting 7 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

3. All of the shares subject to the option are immediately exercisable.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Pepin, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)